Top

Journal of Clinical Psychology in Medical Settings

Published in:

01-09-2012

Cognitive-Behavioral and Pharmacological Interventions for Premenstrual Syndrome or Premenstrual Dysphoric Disorder: A Meta-Analysis

Authors: Maria Kleinstäuber, Michael Witthöft, Wolfgang Hiller

Published in: Journal of Clinical Psychology in Medical Settings | Issue 3/2012

Abstract

The current meta-analysis investigates the efficacy of psychotherapeutic interventions and psychopharmacotherapy for premenstrual syndrome (PMS) and premenstrual dysphoric disorder. Based on a multiple-phase literature search, controlled trials were selected according to a priori defined inclusion criteria. Data were extracted on the basis of a standardized coding scheme. The standardized weighted mean difference (random effects model) was used as effect size index. Dependent on outcome, 22 included studies obtained small to medium effect sizes for cognitive-behavioral interventions (range: d ₊ = 0.24–0.70) and for serotonergic antidepressants (range: d ₊ = 0.29–0.58), at post-assessment. Follow-ups were performed only in studies of cognitive-behavioral interventions (range: d ₊ = 0.46–0.74). There was no evidence of a publication bias. For both cognitive-behavioral interventions and serotonergic antidepressants, efficacy in treatment of PMS was found to not be satisfactory. Future research should possibly focus more on a combination of both approaches.

American College of Obstetricians and Gynecologists. (2000a). Premenstrual syndrome. Washington, DC: National Guideline Clearinghouse.

American College of Obstetricians and Gynecologists. (2000b). Clinical management guidelines for obstetrician–gynecologists: Premenstrual syndrome. ACOG Practice Bulletin, 15, 3–8.

American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC: American Psychiatric Press.

American Psychiatric Association. (1994). Diagnostic and statistical manual for mental disorders (DSM IV). Washington, DC: American Psychiatric Press.

Angst, J., Sellaro, R., Merikangas, K. R., & Endicott, J. (2001). The epidemiology of perimenstrual psychological symptoms. Acta Psychiatrica Scandinavica, 104, 110–116.PubMedCrossRef

*Arredondo-Soberon, F., Freeman, E. W., & Sondheimer, S. J. (1997). Relationship and response of food cravings and depression to sertraline in patients with premenstrual syndrome. Fertility and Sterility, 68(Suppl. 1), S27–S28.

Becker, B. J. (1988). Synthesizing standardized mean-change measures. British Journal of Mathematical and Statistical Psychology, 41, 257−278.CrossRef

Bhatia, S. C., & Bhatia, S. K. (2002). Diagnosis and treatment of premenstrual dysphoric disorder. American Family Physician, 66, 1239–1248.PubMed

*Blake, F., Salkovskis, P., Gath, D., Day, A., & Garrod, A. (1998). Cognitive therapy for premenstrual syndrome: A controlled trial. Journal of Psychosomatic Research, 45, 307–318.

Brown, J., O’Brien, P. M. S., Marjoribanks, J., & Wyatt, K. (2009). Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews, 2009, Art. No.: CD001396. doi:10.1002/14651858.CD001396.pub2.

Busse, J. W., Montori, V. M., Krasnik, C., Patelis-Siotis, I., & Guyatt, G. H. (2008). Psychological intervention for premenstrual syndrome: A meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 78, 6–15.PubMedCrossRef

Campbell, E. M., Peterkin, D., O’Grady, K., & Sanson-Fisher, R. (1997). Premenstrual symptoms in general practice: Prevalence and treatment. Journal of Reproductive Medicine, 42, 637–646.PubMed

Cohen, J. (1977). Statistical power analysis for the behavioral sciences (Rev. ed.). New York: Academic Press.

*Crnobaric, C., Jasovic-Gasic, M., Milovanovic, S., & Miljevic, C. (1998). Treatment of premenstrual dysphoric disorder with fluoxetine during the luteal phase. European Psychiatry, 13(Suppl. 4), 251s.

Cuijpers, P., Van Straten, A., Bohlmeijer, E., Hollon, S. D., & Andersson, G. (2010). The effects of psychotherapy for adult depression are overestimated: A meta-analysis of study quality and effect size. Psychological Medicine, 40, 211–223.PubMedCrossRef

Cunningham, J., Yonkers, K. A., O’Brien, S., & Eriksson, E. (2009). Update on research and treatment of premenstrual dysphoric disorder. Harvard Review of Psychiatry, 17, 120–137.PubMedCrossRef

Endicott, J., & Halbreich, U. (1982). Retrospective reports of depressive premenstrual changes: Factors affecting confirmation by daily ratings. Psychopharmacology Bulletin, 18, 109–112.

*Eriksson, E., Ekman, A., Sinclair, S., Sörvik, K., Ysander, C., Mattson, U. B., et al. (2008). Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 28, 195–202.

Freeman, E. W. (2003). Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology, 28, 25–37.PubMedCrossRef

Freeman, E. W., DeRubeis, R. J., & Rickels, K. (1996). Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Research, 65, 97–106.PubMedCrossRef

Freeman, E. W., & Rickels, K. (1999). Characteristics of placebo responses in medical treatment of premenstrual syndrome. American Journal of Psychiatry, 156, 1403–1408.PubMed

*Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (1995). A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA, 274, 51–57.

*Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (1999). Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial. Archives of General Psychiatry, 56, 932–939.

*Freeman, E. W., Rickels, K., Yonkers, K. A., Kunz, N. R., McPherson, M., & Upton, G. V. (2001). Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics and Gynecology, 98, 737–744.

Glass, G. V., McGaw, B., & Smith, M. L. (1981). Meta-analysis in social research. Beverly Hills, CA: Sage.

Halbreich, U. (2008). Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: Effective but not enough. CNS Spectrums, 13, 569–572.

Halbreich, U., Backstrom, T., Eriksson, E., O’Brien, S., Calil, H., Ceskova, E., et al. (2007). Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecological Endocrinology, 23, 123–130.PubMedCrossRef

*Halbreich, U., Bergeron, R., Yonkers, K. A., Freeman, E., Stout, A. L., & Cohen, L. (2002). Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstetrics and Gynecology, 100, 1219–1229.

Halbreich, U., Bornstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact and burden of premenstrual dysphoric disorder (PMS, PMDD). Psychoneuroendocrinology, 28(Suppl. 3), 1–23.

Hedges, L. V. (1981). Distribution theory for Glass’s estimator of effect size and related estimators. Journal of Educational Statistics, 7, 107–128.CrossRef

Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis. Orlando: Academic Press.

*Hicks, S. M., Walker, A. F., Gallagher, J., Middleton, R. W., & Wright, J. M. (2004). The significance of “nonsignificance” in randomized controlled studies: A discussion inspired by a double-blinded study on St. John’s wort (Hypericum perforatum L.) for premenstrual symptoms. Journal of Alternative and Complementary Medicine, 10, 925–932.

*Hunter, M. S., Ussher, J. M., Browne, S. J., Cariss, M., Jelley, R., & Katz, M. (2002). A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. Journal of Psychosomatic Obstetrics and Gynaecology, 23, 193–199.

*Hunter, M. S., Ussher, J. M., Cariss, M., Browne, S., Jelley, R., & Katz, M. (2002). Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: A study of treatment processes. Journal of Psychosomatic Research, 53, 811–817.

Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, J. M., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17, 1–12.PubMedCrossRef

*Kirkby, R. J. (1994). Changes in premenstrual symptoms and irrational thinking following cognitive behavioral coping skills training. Journal of Consulting and Clinical Psychology, 5, 1026–1032.

*Kornstein, S. G., Pearlstein, T. B., Fayyad, R., Farfel, G. M., & Gillespie, J. A. (2006). Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: Efficacy of 3 dosing strategies. Journal of Clinical Psychiatry, 67, 1624–1632.

*Landén, M., Nissbrandt, H., Allgulander, C., Sörvik, K., Ysander, C., & Eriksson, E. (2007). Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology, 32, 153–161.

Leichsenring, F., Rabung, S., & Leibing, E. (2004). The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders. Archives of General Psychiatry, 61, 1208–1216.PubMedCrossRef

Lipsey, M. W., & Wilson, D. B. (1993). The efficacy of psychological, educational, and behavioral treatment: Confirmation from meta-analysis. American Psychologist, 48, 1181–1209.PubMedCrossRef

Lipsey, M. W., & Wilson, D. B. (2001). Practical meta-analysis. Thousand Oaks, CA: Sage.

*Margolis, A. (1986). The use of a cognitive restructuring intervention in the treatment of premenstrual syndrome: A controlled study (Doctoral dissertation, Ohio University, Ohio, 1985). Dissertation Abstracts International, 47/01-B, 381–716.

Microsoft Office Excel 2003 [Computer software]. (2003). Redmond, WA: Microsoft Corporation.

Moos, R. H. (1986). The development of a menstrual distress questionnaire. Psychosomatic Medicine, 30, 853–867.

*Morse, G. (1999). Positively reframing perceptions of the menstrual cycle among women with premenstrual syndrome. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 28, 165–174.

Orwin, R. G. (1983). A fail-safe N for effect size in meta-analysis. Journal of Educational Statistics, 8, 157–159.CrossRef

*Pearlstein, T. B., Bellew, K. M., Endicott, J., & Steiner, M. (2005). Paroxetine controlled release for premenstrual dysphoric disorder: Remission analysis following a randomized, double-blind, placebo-controlled trial. Primary Care Companion to the Journal of Clinical Psychiatry, 7, 53–60.

*Pearlstein, T. B., Stone, A. B., Lund, S. A., Scheft, H., Zlotnick, C., & Brown, W. A. (1997). Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 17, 261–266.

Pearlstein, T. B., Yonkers, K., Fayyad, R., & Gillespie, J. (2005). Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal of Affective Disorders, 85, 275–282.PubMedCrossRef

Shah, N. R., Jones, J. B., Aperi, J., Shemtov, R., Karne, A., & Borenstein, J. (2008). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. A meta-analysis. Obstetrics and Gynecology, 5, 1175–1182.CrossRef

Sheenan, D. V. (1983). The anxiety disease. New York: Scribner.

*Steiner, M., Ravindran, A. V., LeMelledo, J. M., Carter, D., Huang, J. O., Anonychuk, A. M., et al. (2008). Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled trial in Canadian women. Journal of Clinical Psychiatry, 69, 991–998.

*Steiner, M., Romano, S. J., Babcock, S., Dillon, J., Shuler, C., Berger, C., et al. (2001). The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG International Journal of Obstetrics and Gynaecology, 108, 462–468.

*Steiner, M., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., et al. (1995). Fluoxetine in the treatment of premenstrual dysphoria. New England Journal of Medicine, 332, 1529–1534.

Stone, A. B., Pearlstein, T. B., & Brown, W. A. (1991). Fluoxetine in the treatment of late luteal phase dysphoric disorder. Journal of Clinical Psychiatry, 52, 290–293.PubMed

*Taylor, D. (1999). Effectiveness of professional peer group treatment: Symptom management for women with PMS. Research in Nursing and Health, 22, 496–511.

Thomson, A. B., & Page, L. A. (2007). Psychotherapies for hypochondriasis. Cochrane Database of Systematic Reviews 2007, Art. No.: CD006520. doi:10.1002/14651858.CD006520.pub2.

Van Ree, J. M., Schagen Van Leeuwen, J. H., Koppeschaar, H. P., & Te Velde, E. R. (2005). Unexpected placebo response in premenstrual dysphoric disorder: Implication of endogenous opioids. Psychopharmacology, 182, 318–319.

*Weiss, C. R. (1988). Cognitive-behavioral group therapy for the treatment of premenstrual distress (Doctoral dissertation, State University of New York at Buffalo, New York, 1988). Dissertation Abstracts International, 49/06-B, 2389–2658.

Wilson, D. B. (2005). Meta-analysis macros for SAS, SPSS, and Stata. Retrieved January 22, 2010, from http://mason.gmu.edu/~dwilsonb/ma.html.

Wittchen, H. U., Becker, E., Lieb, R., & Krause, P. (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine, 32, 119–132.PubMedCrossRef

*Yonkers, K. A., Halbreich, U., & Freeman, E. (1997). Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. JAMA, 278, 983–988.

*Yonkers, K. A., Holthausen, G. A., Poschman, K., & Howell, H. B. (2006). Symptom-onset treatment for women with premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 26, 198–202.

Title: Cognitive-Behavioral and Pharmacological Interventions for Premenstrual Syndrome or Premenstrual Dysphoric Disorder: A Meta-Analysis
Authors: Maria Kleinstäuber
Michael Witthöft
Wolfgang Hiller
Publication date: 01-09-2012
Publisher: Springer US
Published in: Journal of Clinical Psychology in Medical Settings / Issue 3/2012
Print ISSN: 1068-9583
Electronic ISSN: 1573-3572
DOI: https://doi.org/10.1007/s10880-012-9299-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cognitive-Behavioral and Pharmacological Interventions for Premenstrual Syndrome or Premenstrual Dysphoric Disorder: A Meta-Analysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Assessing Patients’ Beliefs About Their Cancer-Related Fatigue: Validation of an Adapted Version of the Illness Perception Questionnaire

Dyadic Coping Among Couples with COPD: A Pilot Study

Psychosocial Functioning in Children and Adolescents with Extreme Obesity

Treating Prepartum Depression to Improve Infant Developmental Outcomes: A Study of Diabetes in Pregnancy

Authoritative Parenting, Parenting Stress, and Self-Care in Pre-Adolescents with Type 1 Diabetes

The Role of Parental and Adolescent Attributions in Adjustment of Adolescents with Chronic Illness